Form 4: Nuvalent Director Matthew Shair Sells Shares Under 10b5-1 Trading Plan

Director Matthew Shair of Nuvalent, Inc. executed sales of Class A Common Stock on February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Matthew Shair, a director of Nuvalent, Inc., sold shares of Class A Common Stock on February 24, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 21, 2023.
• A total of 316 shares were sold at a weighted average price of $77.51, with prices ranging from $77.02 to $77.99.
• An additional 1,382 shares were sold at a weighted average price of $78.49, with prices ranging from $78.02 to $79.01.
• Another 302 shares were sold at a weighted average price of $79.13, with prices ranging from $79.02 to $79.90.
• Following these transactions, Shair directly owns 1,427,197 shares of Class A Common Stock.
• Shair also indirectly owns 216,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust, over which he has voting and dispositive power.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives and directors to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates